cmAngio® vs Reveal LINQ Insertable Cardiac Monitor

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

cmAngio®

by CureMetrix

Reveal LINQ Insertable Cardiac Monitor

by Medtronic

AI Verdict

cmAngio® utilizes AI to detect Breast Arterial Calcifications on mammograms, providing insights into cardiovascular risk as a screening tool. In contrast, the Reveal LINQ Insertable Cardiac Monitor is an implantable device that directly monitors cardiac electrical activity with AI to diagnose arrhythmias. While both fall under the umbrella of Cardiology AI, their distinct approaches—image analysis for risk assessment versus direct physiological monitoring for diagnosis—make them adjacent rather than direct competitors.

Choose cmAngio® if…

Choose cmAngio® if you are a healthcare provider seeking to opportunistically assess cardiovascular risk in women using existing mammography data. This AI software non-invasively detects and visualizes Breast Arterial Calcifications (BAC), providing early insights into a patient's cardiovascular health without requiring additional radiation or procedures. It is ideal for integrating cardiovascular screening into routine breast cancer screening workflows.

View cmAngio® →

Choose Reveal LINQ Insertable Cardiac Monitor if…

Choose the Reveal LINQ Insertable Cardiac Monitor if your patient requires long-term, continuous heart monitoring for intermittent cardiac arrhythmias, unexplained syncope, or other conditions where episodic ECG events are difficult to capture. This implantable device, enhanced with AccuRhythm™ AI, offers highly accurate detection of cardiac events while significantly reducing false alerts, providing critical diagnostic yield over an extended period.

View Reveal LINQ Insertable Cardiac Monitor →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	cmAngio®	Reveal LINQ Insertable Cardiac Monitor
Pricing	Paid, out-of-pocket	Contact vendor
Deployment	Cloud-based, integrates with any DICOM-compliant viewer	Implantable device with data transmitted to a cloud-based platform (CareLink™ network) via patient smartphone app or home communicator.
BAA Available	Unknown	Yes AI-estimated
FDA Status	Cleared AI-estimated	Yes AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	cmAngio®	Reveal LINQ Insertable Cardiac Monitor
Product Name	cmAngiou00ae	Reveal LINQ Insertable Cardiac Monitor
Company	CureMetrix	Medtronic
Primary AI Function	AI-based detection of Breast Arterial Calcifications (BAC)	AccuRhythmu2122 AI algorithms for reduced false alerts (AF and Pause)
Data Source/Monitoring Method	Processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams	Continuous, long-term subcutaneous ECG monitoring
Supported Specialties	Cardiology, Obstetrics & Gynecology, Radiology	Cardiology, Pediatrics

Videos

Demos, reviews, and walkthroughs featuring cmAngio® and Reveal LINQ Insertable Cardiac Monitor.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications and target patient populations for cmAngiou00ae and the Reveal LINQ Insertable Cardiac Monitor?

cmAngiou00ae is FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment, primarily for women. The Reveal LINQ Insertable Cardiac Monitor (ICM) is designed for long-term, accurate heart monitoring to diagnose conditions like atrial fibrillation and syncope, and is indicated for patients at increased risk of cardiac arrhythmias or those experiencing transient symptoms suggesting an arrhythmia.

How do these tools acquire and analyze patient data, and what is the level of invasiveness for the patient?

cmAngiou00ae non-invasively analyzes existing Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams using AI software to identify and mark BAC. The Reveal LINQ ICM is an implantable device that provides continuous, long-term subcutaneous ECG monitoring, with data transmitted remotely via a patient smartphone app or home communicator to a cloud-based platform.

What specific role does AI play in each tool to enhance diagnostic accuracy or efficiency?

cmAngiou00ae utilizes AI for the detection and visualization of Breast Arterial Calcifications (BAC) on mammograms, enabling identification and reporting without additional radiation or procedures. The Reveal LINQ ICM incorporates AccuRhythmu2122 AI algorithms to reduce false alerts for atrial fibrillation (AF) and pauses, thereby enhancing diagnostic yield and reducing clinic review burden.

How do these tools support long-term patient management and data review for clinicians?

cmAngiou00ae provides visualization of BAC location on a scorecard, allowing radiologists to incorporate this information into patient assessment and follow-up recommendations. The Reveal LINQ ICM offers continuous monitoring, remote programming capabilities, and an enhanced ECG experience for clinical adjudication through the CareLinku2122 network, with features like CareAlertu2122 notifications and Cardiac Compassu2122 reports.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring cmAngio® or Reveal LINQ Insertable Cardiac Monitor

Backers

Who funded each tool's parent company.

cmAngio®

Keshif Ventures